Amonafide + ara-C in secondary acute myeloid leukemia (sAML): Consistent efficacy in poor risk populations
Publication
, Journal Article
Rizzieri, DA; Erba, HP; O'Donnell, M; Powell, BL; Lundberg, AS; Bennett, JM; Capizzi, RL
Published in: Journal of Clinical Oncology
May 20, 2008
Duke Scholars
Published In
Journal of Clinical Oncology
DOI
EISSN
1527-7755
ISSN
0732-183X
Publication Date
May 20, 2008
Volume
26
Issue
15_suppl
Start / End Page
7027 / 7027
Publisher
American Society of Clinical Oncology (ASCO)
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Rizzieri, D. A., Erba, H. P., O’Donnell, M., Powell, B. L., Lundberg, A. S., Bennett, J. M., & Capizzi, R. L. (2008). Amonafide + ara-C in secondary acute myeloid leukemia (sAML): Consistent efficacy in poor risk populations. Journal of Clinical Oncology, 26(15_suppl), 7027–7027. https://doi.org/10.1200/jco.2008.26.15_suppl.7027
Rizzieri, D. A., H. P. Erba, M. O’Donnell, B. L. Powell, A. S. Lundberg, J. M. Bennett, and R. L. Capizzi. “Amonafide + ara-C in secondary acute myeloid leukemia (sAML): Consistent efficacy in poor risk populations.” Journal of Clinical Oncology 26, no. 15_suppl (May 20, 2008): 7027–7027. https://doi.org/10.1200/jco.2008.26.15_suppl.7027.
Rizzieri DA, Erba HP, O’Donnell M, Powell BL, Lundberg AS, Bennett JM, et al. Amonafide + ara-C in secondary acute myeloid leukemia (sAML): Consistent efficacy in poor risk populations. Journal of Clinical Oncology. 2008 May 20;26(15_suppl):7027–7027.
Rizzieri, D. A., et al. “Amonafide + ara-C in secondary acute myeloid leukemia (sAML): Consistent efficacy in poor risk populations.” Journal of Clinical Oncology, vol. 26, no. 15_suppl, American Society of Clinical Oncology (ASCO), May 2008, pp. 7027–7027. Crossref, doi:10.1200/jco.2008.26.15_suppl.7027.
Rizzieri DA, Erba HP, O’Donnell M, Powell BL, Lundberg AS, Bennett JM, Capizzi RL. Amonafide + ara-C in secondary acute myeloid leukemia (sAML): Consistent efficacy in poor risk populations. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2008 May 20;26(15_suppl):7027–7027.
Published In
Journal of Clinical Oncology
DOI
EISSN
1527-7755
ISSN
0732-183X
Publication Date
May 20, 2008
Volume
26
Issue
15_suppl
Start / End Page
7027 / 7027
Publisher
American Society of Clinical Oncology (ASCO)
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences